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Abstract 
Purpose: To determine excipient and ibuprofen:excipient mixture sensitivity to reprocessing produced 
by either direct compression or wet granulation. 
Methods: The effect of excipient type, technology and reprocessing on flow, compressibility and 
compactibility was assessed using and 8x2x2 factorial design. Design Expert® v.8.01 software was 
employed for data analysis. Pure excipients were processed by direct compression, while the 
ibuprofen:excipient mixtures were processed by wet granulation. Once compacts were produced, they 
were milled and reprocessed using the same technologies, respectively. Excipient properties such as 
particle size, porosity and densities were also evaluated. 
Results: For most excipients, reprocessing caused a 20 – 50 % decrease in particle size and 5 – 80 % 
reduction in porosity, but increased compactibility (10 – 50 %). Flow decreased (30 – 50 %) only for 
highly densified excipients such as calcium carbonate and calcium diphosphate. 
Conclusion: Microcrystalline cellulose and sorbitol are the excipients with the best tableting properties 
when reprocessing is conducted via wet granulation and direct compression platforms, respectively. 
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The most common technologies for the 
production of tablets are direct compression, wet 
and dry granulation, respectively. However, the 
choice of a particular technology depends on the 
physicochemical characteristics of the drug and 
excipients used. Thus, a successful compression 
process by direct compression depends on the 
choice of suitable excipients with excellent 
compressibility, compactibility and flow properties 
among others [1]. Direct compression would be 
the ideal production process because it requires 
fewer unit operations, consumes less energy, is 
more economical and causes no 
physicochemical or microbial stability problems.  
Nevertheless, there are very few multifunctional 
direct compressive excipients because not all of 
them possess adequate tableting and particle 
properties for compaction [2,3]. For this reason, 
~80 % of pharmaceutical production employs the 
wet granulation technology [4]. When the wet 
granulation technology is used, the 
excipient:drug mixture acquires the required flow, 
compressibility and compactibility to facilitate the 
manufacturing process, achieve uniform filling of 
the matrices, regular particle slip and uniform 
application of pressure to the powder bed [5-7]. 
The granulation process could also be performed 
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by dry compaction. This granulation is desirable 
for heat or moisture sensitive drugs [8]. The 
characteristics of the granules produced by direct 
compression and wet granulation influence 
compact hardness, disintegration and drug 
dissolution [9,10]. If hydrophobic drugs are used, 
hydrophilic liquids can be added during wet 
granulation to wet a powder blend to facilitate 
tablet disintegration and drug dissolution [11-14]  
On the other hand, sometimes formulation 
scientists have to face problems related with 
manufacture of compacts due to changes in 
crystallinity, porosity, hygrospicity, particle size 
which have a deleterious effect on critical 
manufacturing properties such as flow, 
compressibility and compactibility of excipients or 
drug:excipients mixtures. For this reason, 
Pharmaceutical scientists are forced to correct 
the defective batches by milling or grinding these 
compacts and adding an appropriate amount of 
material having the most suitable properties to 
correct the intended formulation.  In this case, 
powders improve particle size distribution, 
density, porosity, flow and compression 
characteristics and thus, compacts with adequate 
quality parameters are produced. . The goal of 
this study is to evaluate the susceptibility of 
various excipients to recompression employing 







Pregelatinized cassava (lot CS1102) and 
pregelatinized maize (lot CS1101) were obtained 
from Corn industries (Cali, Columbia). Starch 
1500 (lot IN504089) and ibuprofen (lot QJ0238) 
were acquired from Colorcon (West Point, PA, 
USA) and Spectrum Chemicals  (New Brunswick, 
NJ, USA), respectively. Lactose monohydrate (lot 
8596021361), Avicel PH101 (lot 6N608C), 
calcium carbonate (lot 2256KXDS) were 
obtained from Fonterra (Rosemont, USA), FMC 
Biopolymers (Philadelphia, PA, USA) and 
ProtoKimica (Medellin, Columbia), respectively. 
PVP K-30 (lot 0911106, MW 40,000), sorbitol (lot 
024M0118) and calcium diphosphate (lot 
024M0118) were purchased from Bell Chem 




Particle size was determined on a Ro-Tap sieve 
shaker (RX29, WS Tyler, Mentor, USA) equipped 
with sieves from 44 to 425 µm (Fisher Scientific 
Co., Pittsburgh, PA) and 50 g for all samples 
operated for 15 min. Moisture content was 
determined in 3 g of sample on an infrared 
moisture balance (Scout Pro, OHAUS) at 100 °C 
for 15 min. True density and porosity were 
determined on a Helium pycnometer (AccuPyc II 
1340, Micromeritics, USA) with ~ 1 g of sample. 
Bulk density was determined on 20 g of sample 
directly measured on a 50 mL graduated 
cylinder. Tap density was measured in an 
AutoTap® density analyzer(AT2, Quantachrome 
Instruments, Boynton Beach) operated for 1000 
cycles. Volume data for each cycle were fitted to 
the Kawakita compressibility model [8]. Flow rate 
was determined using 20 g of sample passed 
through a glass funnel with a neck diameter of 13 
mm measuring the flow time. This diameter is 
equivalent to the diameter of the flat-faced 
punches-and-die set used for the compaction 
studies. The ratio between mass and the 
respective time was taken as the flow rate. 
 
Reprocessing susceptibility of pure 
excipients produced by direct compression 
 
Direct compression of ~200 g of a 100 % pure 
excipient was done on an 8-station tablet 
machine (Riddhi Pharma Machinery, 
Gulabnagarahmedabad, India) at 1 rpm using 
flat-faced punches of 13 mm diameter to render 
a 500 mg tablets with a porosity between 10 and 
20 %. Porosity was determined as in Eq 1. 
 
 Ɛ = 1 – (m/ρhπr2)……………………. (1) 
 
where, m, ρ, h and r correspond to the mass, 
true density, height and radius of the tablets. 
These tablets were also analyzed for tensile 
strength determined from the crushing strength 
data (UK200, VanKel, Manasquan, USA) as 
reported previously [9]. Tablets were then 
passed through an oscillating granulator (Riddhi 
Pharma Machinery, India) fitted with a # 20 sieve 
(840 µm pore size), analyzed for particle size, 
porosity and densities. These granules were then 
compressed again under the same conditions. 
  
Reprocessing of excipient:ibuprofen blends 
(60:40) produced by wet granulation 
 
Ibuprofen, which is a poorly compactable drug, 
was used as a model drug since the desirable 
dose for a 500 mg compact is 200 mg. Thus, 200 
g of ibuprofen:excipient (60:40) blends were 
prepared and passed freely through a # 60 sieve 
(250 µm pore size) to remove aggregates and 
mixed in a V-blender for 15 min. The powder was 
then transferred to a ribbon blender (Pharma 
Machinery Riddhi, India) and 20 mL of a 10 % 
PVP solution was added. The wet mass was 
passed through an oscillating granulator (Riddhi 
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Pharma Machinery, India) fitted with #20 mesh 
sieve (840 µm, pore size).  
 
The granules were dried in a fluidized bed dryer 
(Indemec, Medellin, Columbia), analyzed for 
particle size, porosity and densities. These 
granules were then compressed on a tablet 
machine (Riddhi Pharma Machinery, India) at 1 
rpm using 13 mm flat-faced punches tooling to 
render compact of ~500 mg and porosity 
between 10 and 20 %. These tablets were 
analyzed for tensile strength. Compacts were 
then passed through an oscillating granulator 
equipped with a # 20 mesh, tested again and 




A full factorial design was employed for the 
statistical analysis. The validity of this model was 
tested with the ANOVA analysis, lack of fit test 
and a new experimental run. The significance 
level was 0.05 and the statistical analysis was 
conducted using the Design Expert® software 




The factorial experimental matrix with three 
factors is shown in Table 1. This matrix is 
composed of 32 experimental runs, including 
eight different combinations of excipients 
processed by direct compression and in blends 
with ibuprofen processed by wet granulation. 
Excipient blends with ibuprofen and compressed 
by direct compression were not attempted since 
the resulting compacts were so fragile that they 
broke after ejection and thus,  
 
 
Table 1: Full factor factorial design matrix for the combination of three factors (technology, excipient, and 
treatment) 
 










tap (g/cm3) true 
(g/cm3) 
1 2 1 1 14.5 334.3 12.1 2.0 0.14 0.78 2.50 
2 2 2 1 9.4 1693.4 21.6 1.7 0.59 0.71 2.35 
3 8 1 2 12.9 90.5 24.5 4.0 0.23 0.27 1.12 
4 1 1 2 17.3 424.6 65.1 2.4 1.11 1.40 3.00 
5 3 1 1 15.4 81.1 37.5 1.8 0.65 0.77 2.10 
6 1 2 1 1.1 692.9 24.1 4.3 0.70 0.88 1.43 
7 1 2 2 49.5 424.6 44.4 0.9 0.72 1.12 1.39 
8 7 1 1 7.9 50.5 10.7 5.1 0.71 0.77 1.32 
9 6 1 2 20.2 36.7 31.2 3.0 0.71 0.80 1.12 
10 6 1 1 11.9 96.9 14.8 4.2 0.71 0.55 1.01 
11 4 1 1 18.9 83.2 72.3 1.2 1.03 1.25 3.37 
12 5 2 2 12.6 1189.3 24.9 1.2 0.58 0.67 1.36 
13 5 1 2 25.2 300.5 11.0 2.9 0.5 0.66 1.25 
14 2 1 2 16.7 925.4 36.8 1.3 0.14 0.80 2.51 
15 4 1 2 16.2 129.1 50.6 2.6 1.05 1.25 3.28 
16 4 2 2 8.5 59.1 25.4 2.2 0.67 0.74 1.52 
17 1 1 1 9.7 719.4 68.7 2.0 1.11 1.27 2.78 
18 8 1 1 9.7 47.4 17.4 4.7 0.59 0.65 1.12 
19 3 1 2 70.8 49.4 24.8 2.1 0.67 0.83 1.93 
20 4 2 1 10.6 68.2 14.9 2.5 0.67 1.63 1.63 
21 5 2 1 21.9 1356.7 21.5 2.4 0.45 0.57 1.39 
22 5 1 1 21.9 473.3 16.0 2.0 0.45 0.57 1.18 
23 3 2 2 9.7 1348.5 31.1 1.2 0.58 0.67 1.35 
24 8 2 2 11.6 5782.9 30.4 1.0 0.52 0.59 1.33 
25 2 2 2 9.3 1510.4 29.7 2.8 0.59 0.67 2.24 
26 6 2 2 11.7 1950.9 24.9 4.4 0.56 0.65 1.40 
27 7 1 2 12.4 48.9 6.5 5.3 0.71 0.82 1.35 
28 6 2 1 9.7 1181.3 27.1 3.3 0.50 0.57 1.32 
29 7 2 1 5.5 793.0 14.9 4.3 0.52 0.57 1.31 
30 7 2 2 7.9 390.4 20.5 4.1 0.56 0.65 1.26 
31 3 2 1 8.7 50.1 24.8 4.6 0.53 0.57 1.31 
32 8 2 1 12.4 5781 24.3 1.0 0.55 1.25 1.31 
M, material (1. Calcium carbonate; 2. sorbitol, 3. Cassava starch; 4. Calcium diphosphate; 5. Microcrystalline 
cellulose (Avicel® PH101); 6. Pregelatinized starch; 7. Starch1500®; 8. Lactose monohydrate); TEC, technology 
(1. Direct compression; 2. Wet granulation); TT, treatment (1. Processing; 2. Reprocessing); COM, 
compressibility; TS, Tensile strength; FR, flow rate; MC, moisture content 
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were not included in the experimental matrix. The 
selected most critical responses for the tableting 
process were compressibility, compactibility and 
flow rate. Since all materials were dried in an 
oven for 3 h at 105 °C, the moisture content was 
controlled below 5.3 % and hence, this factor 
was not included in the experimental design. 
Further, the contribution of the effects of the 
excipient type, technology and reprocessing on 
densification and packing ability were reflected 
on changes in powder porosity. 
 
Figure 1 shows the variation of particle size and 
porosity with processing and the technology 
used. When materials were direct compressed 
and reprocessed there was an increase in 
particle size of cassava starch and pregelatinized 
starch, whereas the particle size of lactose 
monohydrate decreased. Conversely, when 
granules were produced by wet granulation and 
reprocessed no change in particle size was 
observed, except for calcium carbonate, sorbitol 
and lactose monohydrate.  On the other hand, 
when drug:excipient granules were subjected to 
recompression there was a decrease in porosity, 
except for lactose in which it increased slightly. 
Conversely, for the pure excipients recom-
pression led to an increase in porosity, except for 
starch 1500 where porosity decreased slightly. 
The latter always exhibited a decrease in particle 







Figure 1: Effect of particle size (A) and porosity (B) on processing and reprocessing for pure excipients and in 
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Table 2 shows the analysis of variance for the 
responses studied. The technology used (direct 
compression or wet granulation) and treatment 
(processing or reprocessing) were considered as 
significant for compressibility and flow rate. On 
the contrary, compactibility was affected by all 
three factors. In all cases, the coefficient of 
determination was greater than 0.7038 indicating 
a good fit of the data to the factorial model, being 
the highest for compactibility (0.9750). 
 
The models obtained for the three selected 
properties are: 
 
• Ln(Compressibility) = 2.5-7.759x10-3 * A[1]-0.037 * 
A[2]+0.046 * A[3]+0.012 * A[4]+0.037 * A[5] +0.011 * 
A[6]-5.348x10-3 * A[7]-0.25 * B+0.22 * C-0.042 * 
A[1]C+0.045 * A[2]C-0.074 * A[3]C+2.362x10-3 * 
A[4]C-0.049 * A[5]C+0.024 * A[6]C-1.960x10-3 * A[7]C 
 
• Compactibility = 880.1+86.9 * A[1]+105.4 * A[2]+174 
* A[3]+16.9 * A[4]+171.0 * A[5]+9.6 * A[6] * 2.6 * 
A[7]+636.9 * B+123.4 * A[1]B+91.7 * A[2]B+189.7 * 
A[3]B+17.4 * A[4]B+126  * A[5]B+24.8 * A[6]B-0.82 * 
A[7]B  
 
• Flow rate = 28.3-1.7 * A[1]+0.61 * A[2]-0.26 * 
A[3]+0.64 * A[4]-1.07 * A[5]+0.28 * A[6] +0.21 * A[7]-
2.98 * B+1.14 * A[1]B-0.045 * A[2]B+0.21 * A[3]B-0.49 




The particle size of the lactose was significantly 
reduced after reprocessing by either direct 
compression or wet granulation. This is 
explained by its fragile character upon 
consolidation, since large particles once 
compressed fragment down into smaller particles 
increasing the surface area available for 
compaction and hence, its compactibility 
increased upon reprocessing. Moreover, most of 
the pure excipients processed by direct 
compression had an increase in porosity after 
reprocessing. This implies an increase in the 
number of spaces between fine particles, 
increase of specific surface area and reduction of 
powder density keeping a large amount of air 
within particle micropores causing a decrease in 
flowability. On the contrary, when wet granulation 
took place porosity decreased slightly due to the 
formation of larger regular granules along with a 
low percentage of fines (<5 %). 
 
However, this behavior was only significant for 
microcrystalline cellulose. Therefore, granules 
were able to settle more readily on the die bed 
improving their flow. 
  
Reprocessing improved the compressibility of 
calcium carbonate and cassava starch. However, 
the compressibility of their granules in mixtures 
 











(MS) F-value P-value 
      
Source of  variation      
Model 10.2 16 0.6 2.2 0.064 
Material (A) 2.3 7 0.3 1.2 0.382 
Technology (B ) 2.0 1 2.0 7.1 0.018 
Treatment (C) 1.6 1 1.6 5.5 0.033 
AC 4.3 7 0.6 2.1 0.103 
Residual 4.3 15 0.3   
Total corrected 14.5 31  r2 0.7038 
Compactibility      
Model 6.0x107 15 4.0x106 41.6 < 0.0001 
Material (A) 2.2x107 7 3.2x106 33.2 < 0.0001 
Technology (B) 1.3x107 1 1.3x107 136.25 < 0.0001 
AB 2.4x107 7 3.5x106 36.5 < 0.0001 
Residual 1.5x106 16 95272.9   
Total corrected 6.1x107 31  r2 0.9750 
Flow rate      
Model 7102.4 15 473.5 6.5 0.0003 
Material (A) 4098.2 7 585.5 8.0 0.0003 
Technology (B) 284.5 1 284.5 3.9 0.066 
AB 2719.6 7 388.5 5.3 0.003 
Residual 1166.9 16 72.9   
Total corrected 8269.2 31  r2 0.8589 
    SS=n*∑(Y- )2, , DF=n-1, , MS=SS/DFF=MSi/MSj 
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with ibuprofen decreased. Except for calcium 
diphosphate, the compactibility of the granules 
was better than that of the powders. This effect 
was most salient for lactose. Furthermore, the 
wet granulation process improved flow for 
Starch1500® and Avicel, whereas flow 
decreased for calcium carbonate and calcium 
phosphate using the same technology. 
 
In general, the increase in porosity in the 
powered excipients was more pronounced than 
the increase in porosity of the granules. This 
indicates that opposite to powders, granules 
formed after grinding and subsequent 
reprocessing either maintained or increased in 
size preventing densification or volume 
reduction. The above results proved that the 
volume reduction ability or compressibility of the 
excipients decreased during the wet granulation 
process due to the formation of large and regular 
particles with low porosity and a greater packing 
capacity in the die bed (Fig 2). Thus, the 
granules do not have enough space for a further 
volume reduction. This behavior was not affected 
by reprocessing, indicating that when tablets are 
reprocessed they broke and formed granules or 
aggregates as initially observed. Except for 
calcium diphosphate, compactibility was higher 
for compacts produced by wet granulation rather 






Figure 2: Excipient functionality. TEC, Technology, TM, type of material, 1. Change of compressibility with 
processing: (A) Direct compression, (B) wet granulation (excipient:ibuprofen mixtures). 2. Change of 
compressibility with reprocessing: (A) Direct compression (B) wet granulation. 3. Change of compactibility with 
processing: (A) Direct compression (B) wet granulation. 4. Change of compactibility with reprocessing: (A) Direct 
compression (B) wet granulation. 5. Change of flow rate with processing: (A) Direct compression (B) wet 
granulation. 6. Change of flow rate with reprocessing: (A) Direct compression (B) wet granulation. 1, Calcium 
carbonate; 2, Sorbitol, 3. Cassava starch; 4, Calcium diphosphate; 5, microcrystalline cellulose; 6, pregelatinized 
starch; 7, Starch1500; and 8. Lactose monohydrate 
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Table 3: Comparison between theoretical and experimental values of excipient properties 
 
 Factor   Theoretical  Experimental  
          
Run Material Technology Treatment COM TS FR COM TS FR 
    (%) (kPa) (g/s) (%) (kPa) (g/s) 
A Microcrystalline Wet Processing 7.0 273.0 3.2 1.9 356.7 21.5 
 cellulose granulation        
B Sorbitol Direct Reprocessing 6.0 629.9 4.4 6.7 25.4 36.8 
  compression        
COM, compressibility, TS, tensile strength, FR, Flow rate 
 
explained by the increase in plasticity of the 
materials due to the contribution of the wet 
binder (PVP-k30) compensating the brittle 
behavior of ibuprofen. As a result, compacts with 
a high tensile strength are obtained. In the case 
of lactose, the ductile behavior was so high that 
their tablets deformed before breaking producing 
compacts of very high tensile strength. 
Therefore, PVP-k30 counteracted the combined 
brittle behavior of lactose and ibuprofen 
altogether. It is plausible that the presence of 
water in the hydrate form also contributed to 
ductility. However, this was not reflected in the 
resulting moisture content which was ~ 1.0 % 
due to the presence of bound water (Table 1). 
 
In general, excipients both treated by direct 
compression or wet granulation and further 
recompressed showed a decrease in 
compactibility except for sorbitol, microcrystalline 
cellulose, lactose monohydrate and 
pregelatinized starch. This indicates that particle 
cohesiveness remained unaffected by 
recompression and thus, these excipients are 
also expected to withstand the process of dry 
granulation by double compression. 
 
Moreover, the excipient flow was virtually 
unaffected except for inorganic excipients such 
as calcium carbonate and calcium diphosphate 
(Figure 2). This was ascribed to their high bulk 
and tap densities (1.1 g/cm3 and 1.5 g/cm3, 
respectively), which decreased (0.7 and 1.13 
g/cm3, respectively) after reprocessing 
independent of the technology used. 
 
The combination of factors from the models 
which predict a compressibility between 15-30 %, 
tensile strength from 500 to 5000 kPa and flow 
rate between 15-30 g/s determined 
microcrystalline cellulose and sorbitol as the 
excipients with the best properties for use for wet 
granulation and direct compression, respectively 
and eventually can withstand reprocessing if 
needed (Table 3). All other excipients did not 
match the range for the optimal performance of 
these previously described properties. The 
proximity of the experimental values to the 





Based on the desired range for compressibility, 
tensile strength and flow rate microcrystalline 
cellulose resulted as the best excipient for the 
production of ibuprofen compacts by wet 
granulation, whereas sorbitol was the best of its 
kind for direct compression if reprocessing is 
eventually needed. On the other hand, 
reprocessing increased excipient porosity, while 
it remained virtually unchanged for ibuprofen: 
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